The FDA approved the first heart valve that widens as a child grows

The Food and Drug Administration on October 1, 2026 approved the Autus Size-Adjustable Valve, a surgically implanted pulmonary heart valve that doctors can widen with a balloon catheter after it is in place. It starts at about 13 mm and can later be expanded to about 22 mm. The agency calls it the first heart valve designed to grow with children, and it cleared the device through premarket approval, its most stringent marketing pathway.

The approval is aimed at children born with congenital pulmonary valve disease, including pulmonary valve stenosis and pulmonary valve atresia. The FDA says the heart defects the valve treats affect about 4,200 babies in the United States each year. Autus Valve Technologies developed the device, and the approval went to Edwards Lifesciences.

Balloon expansion in place of repeat open-heart operations

A replacement valve that cannot change size has an obvious flaw in a growing child: the heart gets bigger and the valve does not. Doctors then face a choice between living with a valve that is too small and returning to the operating room for a larger one, sometimes more than once before adulthood. The FDA announcement describes the new valve as first implanted at about 13 mm, a size suited to a toddler or preschool-aged child, and then enlarged in steps as the patient grows.

The enlargement happens through a balloon catheter, a thin tube threaded to the valve and inflated, which stretches the valve toward its 22 mm upper size without a new chest operation.

Michelle Tarver, the director of the FDA’s Center for Devices and Radiological Health, said the Autus valve “gives doctors the option of far fewer trips to the operating room.” The wording matters: fewer, not none. The first operation to implant the valve is still surgery, and the benefit comes afterward. Acting FDA Commissioner Kyle Diamantas called the approval “a historic turning point” and a landmark. The agency’s own account of how the valve behaved in real patients gives that claim some grounding. Valve performance began to deteriorate in two patients who were outgrowing the device, and in both cases the valve was expanded successfully without invasive surgery, which is the scenario the design exists to handle.

Six-month results in 62 pediatric patients

Approval rested on a clinical study that enrolled 62 pediatric patients at 12 U.S. sites. At six months, the first 60 patients showed acceptable hemodynamic performance, meaning blood moved through the valve in a healthy way, with no more than mild pulmonary regurgitation, the backward leak that a failing valve allows. According to the FDA, every implant procedure was successful, and there were no deaths, no clot-related complications requiring treatment and no strokes.

The study was not free of problems. Three patients had a fracture in the valve frame, and two had reduced movement of one leaflet. The FDA reports that none of these findings caused symptoms. One-year follow-up suggests the polymeric leaflets, the flexible flaps that open and close with each heartbeat, hold up well over time, though a year is short against the many years a child will carry the implant.

The record also leaves obvious questions open. A 62-patient single study cannot rule out rare complications, and the agency says experience with the valve is limited and that longer-term studies are ongoing. Whether frame fractures become more common or more serious with age, and how many expansions a typical child needs, are the kind of answers that only years of follow-up can supply.

A premarket approval, not a humanitarian exemption

The regulatory label is worth getting right, because several different FDA routes sound alike. Premarket approval, governed by 21 CFR part 814, applies to class III devices and requires data providing reasonable assurance that the device is safe and effective for its intended use. The agency’s premarket approval program is the route used for the highest-risk implants, and the Autus valve went through it.

That differs from a humanitarian device exemption, a separate pathway for devices serving small patient populations, which the FDA did not use here. It also differs from the De Novo process, which classifies novel devices of low to moderate risk, and from a 510(k) clearance, which depends on similarity to a device already on the market. A full approval means the study data were judged to meet the standard directly.

The indication is narrow. The announcement names pediatric patients with congenital pulmonary valve disease, including pulmonary valve stenosis and pulmonary valve atresia, and it does not state a specific age range. The valve is a pulmonary valve, which sits on the right side of the heart, so the approval says nothing about the aortic or mitral valves. The word first in the FDA’s announcement refers to a valve designed to grow with children, not to every heart valve ever used in a child.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview